Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jay Flatley, Tristan Orpin, Christian Henry, Greg Heath, Greg Yap, and More


Illumina recently announced a reorganization, accompanied by changes in managerial duties, that will take effect on Jan. 1, 2014.

President and CEO Jay Flatley will continue to serve as CEO, but the company will separate the two positions and appoint a new president.

The company is also reorganizing into five business units. Kirk Malloy, currently vice president of Customer Solutions will head the Life Sciences business unit. Tristan Orpin, currently chief commercial officer, will head the Reproductive and Genetic Health business unit. Christian Henry, currently SVP and general manager of the Genomic Solutions business will take over as chief commercial officer.

Rick Klausner, Illumina's chief medical officer, will serve as interim leader of the Oncology business unit. Nick Naclerio will head the Enterprise Informatics business unit, while continuing in his current role as SVP of corporate development. And Matt Posard will lead Illumina's newly created New and Emerging Markets business unit. Posard is currently SVP and general manager of Illumina's Translational and Consumer Genomics business.

Additionally, Greg Heath will move from his position as SVP and general manager of Illumina's Diagnostics business unit to SVP of IVD Development. Bob Ragusa will join the company in December as SVP of Operations.

Quality and Regulatory Affairs will become two separate functions with Regulatory Affairs being folded into IVD Development. Melina Cimler will serve as VP of Quality.

Greg Yap has been named CEO and a director of protein analysis company Biodesy.

Previously, Yap held several management roles at Affymetrix, including vice president of DNA products and vice president of molecular diagnostics. More recently, he was the first healthcare entrepreneur in residence at GE, and was lifecycle leader of advanced staining assays at Ventana Medical Systems.

Sid Taubenfeld has joined Arrayit's board of directors.

Taubenfeld has served as an analyst for a number of Wall Street hedge funds, including Balyasny Asset Management, RH Capital, and PAW Partners. Additionally, Taubenfeld served as director of communications and strategic initiatives for Celsion Corp.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.